Annual Report 2024
Department of Thoracic Surgery
Shun-ichi Watanabe, Yukihiro Yoshida, Tomohiro Haruki, Masaya Yotsukura, Chihiro Takemura, Masahiro Adachi, Atsushi Kosuge, Ryuhei Sakata, Naoyuki Oka, Hiromu Keira, Hiroyuki Tsuchida, Asuka Uebayashi, Mari Okuma, Ryota Kiriyama, Ayaka Makita, Yuki Yamada, Daiki Yoshikawa
Introduction
The Department of Thoracic Surgery deals with various kinds of neoplasms and allied diseases in the thorax, except the esophagus. These include both primary and metastatic lung tumors, mediastinal tumors, pleural tumors (mesotheliomas) and chest wall tumors. The main clinical activity of our department and the subject of most of its research activities has been the surgical management of patients with lung cancer.
The Team and What We Do
Our department has 4 attending surgeons and resident surgeons who perform all the inpatient care, surgeries, examinations, and outpatient care. In 2024, we performed a total of 737 operations, including primary lung cancer in 649, metastatic lung tumors in 10, mediastinal tumors in 32 and other tumors in 46 patients with low morbidity and mortality (Tables 1, 2 and 3). The treatment strategy for patients with lung cancer is based on tumor histology (non-small cell vs. small cell), the extent of the disease (clinical stage) and the physical status of the patient. Surgical resection is usually indicated for clinical stages I, II and some III with non-small cell lung cancer [NSCLC] and clinical stage I with small cell lung cancer [SCLC] in patients with lung cancer. Whereas, to improve the poor prognosis of patients with clinically and histologically proven mediastinal lymph node metastasis or with invasion of vital neighboring structures, optimal treatment modalities are sought in a clinical trial setting. In addition, adjuvant therapy has often been given to patients with advanced lung cancer, even after complete resection. For metastatic lung tumors, resection has been attempted based on Thomford’s criteria. For mediastinal tumors, thymic epithelial tumors are most commonly encountered for resection. Meanwhile, treatment must be carefully determined by cytologic/histologic diagnosis preoperatively in the mediastinum, where various tumor histologies can arise. As for meetings, there are two department meetings. One is for the preoperative evaluation and postoperative inpatient review on Fridays and the other is for the journal club on Wednesdays.
Table 1. Details of resected disease
Table 2. Details of surgical procedures
Table 3. Features of our department
Research Activities
Lymph node dissection for lung cancer has been a major issue in lung cancer treatment and has been extensively studied in our department. We continue to improve our surgical dissection technique, taking oncological and surgical aspects into consideration: a more effective and less invasive lymph node dissection called “selective mediastinal/hilar dissection”, according to the primary tumor location by the lobe. Minimally invasive open surgery (MIOS) is also an important challenge in our department. Recently, the role of segmentectomy has become more important because of the increasing detection rate for early-stage NSCLC. We have actively performed segmentectomy in recent years. In 2023, we performed the largest number of segmentectomies as well as lung cancer surgeries in Japan.
Clinical Trials
Our department has played an important role as a leading hospital in the Japan Clinical Oncology Group (JCOG) - Lung Cancer Surgical Study Group (LCSSG). To date, the LCSSG has conducted a lot of clinical trials for lung cancer surgery.
With the increased frequency of the early detection rate of small-sized or ground-glass opacity (GGO) lung tumors, the optimal mode of resection: limited resection (segmentectomy and wedge resection) or standard resection (lobectomy) remains controversial. In addition, GGO tumors are well known to have an indolent behavior, so some cases might be followed up with careful monitoring by CT. Accordingly, the best management of such patients not only with resection but also with observation needs to be explored. Three clinical trials to determine the appropriateness of limited resection for early-stage NSCLC (JCOG0802, JCOG0804, and JCOG1211) have been conducted since the end of 2009. The results of these 3 trials were published, and the role of limited resection has been established. These 3 trials from the LCSSG could lead to major shifts in clinical practice towards limited resection for early-stage NSCLC. For GGO tumors, JCOG1906: a prospective evaluation of watchful waiting for early-stage lung cancer with GGO opened to accrual in June 2020. JCOG2217: a prospective randomized trial comparing lobectomy vs. segmentectomy for solid dominant tumor 2.1-3.0 cm in size opened to accrual in March 2024.
Investigating the appropriate resection mode for compromised patients is also crucial. Three clinical trials are ongoing: JCOG1708, sublobar resection versus lobectomy for patients with resectable stage I NSCLC with idiopathic pulmonary fibrosis (opened to accrual in May 2018); JCOG1909, anatomical segmentectomy versus wedge resection in high-risk operable patients with clinical stage IA NSCLC (opened to accrual in April 2020); and JCOG2109, anatomical segmentectomy versus wedge resection for small (≤2 cm) peripheral NSCLC in 80 or more aged elderly patients (opened to accrual in October 2022). In addition, JCOG1710A, daily living activities in elderly patients who have undergone lung cancer surgery, completed the full accrual of 986 patients.
As for lymph node dissection, JCOG1413: lobe-specific versus systematic nodal dissection for c-stage I/II NSCLC, completed the full accrual of 1507 patients. We await the maturation of follow-up data.
Regarding adjuvant or neoadjuvant therapy, JCOG1916: postoperative radiotherapy for pathological N2 NSCLC with adjuvant chemotherapy opened to accrual in January 2021. Furthermore, JCOG1807C: efficacy and safety of durvalumab before and after operation or durvalumab as maintenance therapy after chemoradiotherapy against superior sulcus NSCLC opened to accrual in September 2020.
The relevance of postoperative follow-up and surveillance modalities remains debated after the NSCLC resection. JCOG2012: postoperative surveillance for pathological stage II-IIIA NSCLC opened to accrual in October 2022. The LCSSG in the JCOG continues to establish ideal surgical treatment strategies for lung cancer.
Future Prospects
The Thoracic Surgery Group will continue to work together to contribute to the advancement of medical treatment and research into lung cancer, one of the most difficult cancers to treat.
List of papers published in 2024
Journal
1. Kojima N, Nishino S, Sasahara Y, Taki T, Imada H, Miyoshi T, Watanabe SI, Ishii G, Yatabe Y, Mori T, Yoshida A. Inflammatory spindle cell PEComa of the lung with YAP1::TFE3 fusion: a report of two cases and a potential relationship with clear cell stromal tumour. Histopathology, 86:365-372, 2025
2. Nakagawa K, Watanabe SI, Wakabayashi M, Yotsukura M, Mimae T, Hattori A, Miyoshi T, Isaka M, Endo M, Yoshioka H, Tsutani Y, Isaka T, Maniwa T, Nakajima R, Suzuki K, Aokage K, Saji H, Tsuboi M, Okada M, Asamura H, Sekino Y, Nakamura K, Fukuda H. Risk Factors for Locoregional Relapse After Segmentectomy: Supplementary Analysis of the JCOG0802/WJOG4607L Trial. Journal of thoracic oncology, 20:157-166, 2025
3. Sekino Y, Hishida T, Yoshioka H, Wakabayashi M, Mitome N, Shiono S, Kenmotsu H, Nosaki K, Aokage K, Horinouchi H, Fukuda H, Ohe Y, Watanabe SI. Protocol summary of a randomized phase III study: comparing systemic therapy with and without debulking surgery (primary tumour resection) for clinical stage IVA (cT1-2bN0-1M1a) non-small cell lung cancer with radiologically undetermined pleural dissemination JCOG2103 (DEBULK-LUNG). Japanese journal of clinical oncology, 55:176-182, 2025
4. Kayawake H, Okami J, Shintani Y, Ito H, Ohtsuka T, Toyooka S, Mori T, Watanabe SI, Asamura H, Chida M, Endo S, Kadokura M, Nakanishi R, Miyaoka E, Yoshino I, Date H. Predictors of nodal upstaging in clinical N1 nonsmall cell lung cancer. Japanese journal of clinical oncology, 55:283-289, 2025
5. Blechter B, Hsiung CA, Wang X, Zhang H, Seow WJ, Shi J, Chatterjee N, Kim HN, Wong MP, Hong YC, Wong JYY, Dai J, Hosgood HD, Wang Z, Chang IS, Choi J, Wang J, Song M, Hu W, Zheng W, Kim JH, Zhou B, Albanes D, Shin MH, Chung LP, An SJ, Zheng H, Yatabe Y, Zhang XC, Kim YT, Shu XO, Kim YC, Vermeulen RCH, Bassig BA, Chang J, Man Ho JC, Ji BT, Kubo M, Daigo Y, Momozawa Y, Kamatani Y, Honda T, Kunitoh H, Watanabe SI, Miyagi Y, Nakayama H, Matsumoto S, Tsuboi M, Goto K, Yin Z, Takahashi A, Goto A, Minamiya Y, Shimizu K, Tanaka K, Wu T, Wei F, Su J, Kim YH, Oh IJ, Fun Lee VH, Su WC, Chen YM, Chang GC, Chen KY, Huang MS, Lin HC, Seow A, Park JY, Kweon SS, Chen CJ, Gao YT, Wu C, Qian B, Lu D, Liu J, Jeon HS, Hsiao CF, Sung JS, Tsai YH, Jung YJ, Guo H, Hu Z, Chen TY, Burdett L, Yeager M, Hutchinson A, Berndt SI, Wu W, Wang J, Choi JE, Park KH, Sung SW, Liu L, Kang CH, Chen CH, Xu J, Guan P, Tan W, Wang CL, Loon Sihoe AD, Chen Y, Choi YY, Kim JS, Yoon HI, Cai Q, Park IK, Xu P, He Q, Chen CY, Wu J, Lim WY, Chen KC, Chan JKC, Li J, Chen H, Yu CJ, Jin L, Fraumeni JF Jr, Liu J, Landi MT, Yamaji T, Yang Y, Hicks B, Wyatt K, Li SA, Ma H, Song B, Wang Z, Cheng S, Li X, Ren Y, Iwasaki M, Zhu J, Jiang G, Fei K, Wu G, Chien LH, Tsai FY, Yu J, Stevens VL, Yang PC, Lin D, Chen K, Wu YL, Matsuo K, Rothman N, Shiraishi K, Shen H, Chanock SJ, Kohno T, Lan Q. Polygenic Risk Score and Lung Adenocarcinoma Risk Among Never-Smokers by EGFR Mutation Status: A Brief Report. Journal of thoracic oncology, 20:521-530, 2025
6. Masuda K, Yoshida T, Motoi N, Shinno Y, Matsumoto Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Watanabe SI, Hoshino T, Yatabe Y, Ohe Y. Schlafen 11 Expression in Patients With Small Cell Lung Cancer and Its Association With Clinical Outcomes. Thoracic cancer, 16:e15529, 2025
7. Kosuge A, Yoshida Y, Yotsukura M, Watanabe SI. En bloc upper and lower lobe bisegmentectomy for non-small-cell lung cancer invading the fissure. Japanese journal of clinical oncology, 55:194-197, 2025
8. Nakagawa K, Watanabe SI, Wakabayashi M, Sekino Y. A Response to Letter to the Editor: "Refining Risk Stratification for Locoregional Relapse in Clinical Stage IA Small-Sized Peripheral NSCLC After Segmentectomy". Journal of thoracic oncology, 20:e22-e23, 2025
9. Nakagawa K, Watanabe SI, Wakabayashi M, Sekino Y. A Response to the Letter to the Editor: "Sites of Primary Tumors as Crucial Points When Conducting Segmentectomy for NSCLC". Journal of thoracic oncology, 20:e24-e25, 2025
10. Nakagawa K, Watanabe SI, Wakabayashi M, Sekino Y. A Response to Letter to the Editor: "Considerations on Genetics and Treatment Factors in NSCLC Segmentectomy Outcomes". Journal of thoracic oncology, 20:e27-e28, 2025
11. Ikeda S, Ogura T, Miyaoka E, Sekine I, Shukuya T, Takayama K, Inoue A, Okamoto I, Seike M, Takahashi K, Yamamoto N, Yotsukura M, Watanabe SI, Shintani Y. Survival benefit and potential markers of chemotherapy for elderly and poor performance status patients with advanced non-small cell lung cancer: Results from the Japanese Joint Committee of lung cancer registry database. Lung cancer (Amsterdam, Netherlands), 200:108102, 2025
12. Torasawa M, Yoshida T, Shiraishi K, Yagishita S, Ono H, Uehara Y, Miyakoshi J, Tateishi A, Igawa YS, Higashiyama RI, Mochizuki A, Masuda K, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Hamamoto R, Yamamoto N, Watanabe SI, Yatabe Y, Takahashi K, Kohno T, Ohe Y. Implications of EGFR expression on EGFR signaling dependency and adaptive immunity against EGFR-mutated lung adenocarcinoma. Lung cancer (Amsterdam, Netherlands), 202:108494, 2025
13. Maniwa T, Okami J, Miyoshi T, Wakabayashi M, Yoshioka H, Mimae T, Endo M, Hattori A, Nakagawa K, Isaka T, Isaka M, Kita R, Sekino Y, Mitome N, Aokage K, Saji H, Nakajima R, Okada M, Tsuboi M, Asamura H, Fukuda H, Watanabe SI. Lymph node dissection in small peripheral lung cancer: Supplemental analysis of JCOG0802/WJOG4607L. The Journal of thoracic and cardiovascular surgery, 168:674-683.e1, 2024
14. Van Schil PE, Asamura H, Nishimura KK, Rami-Porta R, Kim YT, Bertoglio P, Cangir AK, Donington J, Fang W, Giroux DJ, Lievens Y, Liu H, Lyons G, Sakai S, Travis WD, Ugalde P, Jeffrey Yang CF, Yotsukura M, Detterbeck F. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revisions of the T-Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer. Journal of thoracic oncology, 19:749-765, 2024
15. Mochizuki A, Shiraishi K, Honda T, Higashiyama RI, Sunami K, Matsuda M, Shimada Y, Miyazaki Y, Yoshida Y, Watanabe SI, Yatabe Y, Hamamoto R, Kohno T. Passive Smoking-Induced Mutagenesis as a Promoter of Lung Carcinogenesis. Journal of thoracic oncology, 19:984-994, 2024
16. Rami-Porta R, Nishimura KK, Giroux DJ, Detterbeck F, Cardillo G, Edwards JG, Fong KM, Giuliani M, Huang J, Kernstine KH Sr, Marom EM, Nicholson AG, Van Schil PE, Travis WD, Tsao MS, Watanabe SI, Rusch VW, Asamura H. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer. Journal of thoracic oncology, 19:1007-1027, 2024
17. Travis WD, Eisele M, Nishimura KK, Aly RG, Bertoglio P, Chou TY, Detterbeck FC, Donnington J, Fang W, Joubert P, Kernstine K, Kim YT, Lievens Y, Liu H, Lyons G, Mino-Kenudson M, Nicholson AG, Papotti M, Rami-Porta R, Rusch V, Sakai S, Ugalde P, Van Schil P, Yang CJ, Cilento VJ, Yotsukura M, Asamura H. The International Association for the Study of Lung Cancer (IASLC) Staging Project for Lung Cancer: Recommendation to Introduce Spread Through Air Spaces as a Histologic Descriptor in the Ninth Edition of the TNM Classification of Lung Cancer. Analysis of 4061 Pathologic Stage I NSCLC. Journal of thoracic oncology, 19:1028-1051, 2024
18. Fukuda H, Arai K, Mizuno H, Nishito Y, Motoi N, Arai Y, Hiraoka N, Shibata T, Sonobe Y, Kayukawa Y, Hashimoto E, Takahashi M, Fujii E, Maruyama T, Kuwabara K, Nishizawa T, Mizoguchi Y, Yoshida Y, Watanabe SI, Yamashita M, Kitano S, Sakamoto H, Nagata Y, Mitsumori R, Ozaki K, Niida S, Kanai Y, Hirayama A, Soga T, Tsukada K, Yabuki N, Shimada M, Kitazawa T, Natori O, Sawada N, Kato A, Yoshida T, Yasuda K, Ochiai A, Tsunoda H, Aoki K. Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments. Cancer science, 115:1763-1777, 2024
19. Sakashita M, Motoi N, Yamamoto G, Gambe E, Suzuki M, Yoshida Y, Watanabe SI, Takazawa Y, Aoki K, Ochiai A, Sakashita S. An algorithm-based technique for counting mitochondria in cells using immunohistochemical staining of formalin-fixed and paraffin-embedded sections. Journal of cancer research and clinical oncology, 150:172, 2024
20. Detterbeck FC, Ostrowski M, Hoffmann H, Rami-Porta R, Osarogiagbon RU, Donnington J, Infante M, Marino M, Marom EM, Nakajima J, Nicholson AG, van Schil P, Travis WD, Tsao MS, Edwards JG, Asamura H. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the Classification of Residual Tumor After Resection for the Forthcoming (Ninth) Edition of the TNM Classification of Lung Cancer. Journal of thoracic oncology, 19:1052-1072, 2024
21. Tane S, Okami J, Maniwa Y, Shintani Y, Ito H, Ohtsuka T, Toyooka S, Mori T, Watanabe SI, Chida M, Endo S, Nakanishi R, Kadokura M, Suzuki H, Miyaoka E, Yoshino I, Date H. Clinical outcomes of left upper segmentectomy vs. lobectomy for early non-small-cell lung cancer: a nationwide database study in Japan. Surgery today, 54:1162-1172, 2024
22. Yoshizumi Y, Yokota Y, Ishikawa T, Nagae K, Watanabe SI, Nakamura Y, Kouno K. Quantitative identification of causes of instrumental acoustic signal distortion in Global Navigation Satellite System-Acoustics Combination observations. The Journal of the Acoustical Society of America, 155:2786-2793, 2024
23. Tane K, Shiono S, Wakabayashi M, Kataoka T, Mitome N, Fukuda H, Aokage K, Watanabe SI. A randomized phase III trial of postoperative surveillance for pathological stage II and IIIA non-small cell lung cancer (JCOG2012, PHOENIX). Japanese journal of clinical oncology, 54:926-929, 2024
24. Fujiwara W, Yotsukura M, Yoshida Y, Nakagawa K, Kashima J, Yatabe Y, Watanabe SI. Clinical and Pathologic Differences between Small-Cell Carcinoma and Large-Cell Neuroendocrine Carcinoma of the Lung. Annals of surgical oncology, 31:5697-5705, 2024
25. Kaneko S, Takasawa K, Asada K, Shiraishi K, Ikawa N, Machino H, Shinkai N, Matsuda M, Masuda M, Adachi S, Takahashi S, Kobayashi K, Kouno N, Bolatkan A, Komatsu M, Yamada M, Miyake M, Watanabe H, Tateishi A, Mizuno T, Okubo Y, Mukai M, Yoshida T, Yoshida Y, Horinouchi H, Watanabe SI, Ohe Y, Yatabe Y, Saloura V, Kohno T, Hamamoto R. Mechanism of ERBB2 gene overexpression by the formation of super-enhancer with genomic structural abnormalities in lung adenocarcinoma without clinically actionable genetic alterations. Molecular cancer, 23:126, 2024
26. Blechter B, Wang X, Shi J, Shiraishi K, Choi J, Matsuo K, Chen TY, Dai J, Hung RJ, Chen K, Shu XO, Kim YT, Choudhury PP, Williams J, Landi MT, Lin D, Zheng W, Yin Z, Zhou B, Wang J, Seow WJ, Song L, Chang IS, Hu W, Chien LH, Cai Q, Hong YC, Kim HN, Wu YL, Wong MP, Richardson BD, Li S, Zhang T, Breeze C, Wang Z, Bassig BA, Kim JH, Albanes D, Wong JY, Shin MH, Chung LP, Yang Y, An SJ, Zheng H, Yatabe Y, Zhang XC, Kim YC, Caporaso NE, Chang J, Man Ho JC, Kubo M, Daigo Y, Song M, Momozawa Y, Kamatani Y, Kobayashi M, Okubo K, Honda T, Hosgood HD, Kunitoh H, Watanabe SI, Miyagi Y, Nakayama H, Matsumoto S, Horinouchi H, Tsuboi M, Hamamoto R, Goto K, Ohe Y, Takahashi A, Goto A, Minamiya Y, Hara M, Nishida Y, Takeuchi K, Wakai K, Matsuda K, Murakami Y, Shimizu K, Suzuki H, Saito M, Ohtaki Y, Tanaka K, Wu T, Wei F, Dai H, Machiela MJ, Su J, Kim YH, Oh IJ, Fun Lee VH, Chang GC, Tsai YH, Che KY, Huang MS, Su WC, Chen YM, Seow A, Park JY, Kweon SS, Chen KC, Gao YT, Qian B, Wu C, Lu D, Liu J, Schwartz AG, Houlston R, Spitz MR, Gorlov IP, Wu X, Yang P, Lam S, Tardon A, Chen C, Bojesen SE, Johansson M, Risch A, Bickeböller H, Ji BT, Wichmann HE, Christiani DC, Rennert G, Arnold S, Brennan P, McKay J, Field JK, Davies MPA, Shete SS, Le Marchand L, Liu G, Andrew A, Kiemeney LA, Zienolddiny-Narui S, Grankvist K, Johansson M, Cox A, Taylor F, Yuan JM, Lazarus P, Schabath MB, Aldrich MC, Jeon HS, Jiang SS, Sung JS, Chen CH, Hsiao CF, Jung YJ, Guo H, Hu Z, Burdett L, Yeager M, Hutchinson A, Hicks B, Liu J, Zhu B, Berndt SI, Wu W, Wang J, Li Y, Choi JE, Park KH, Sung SW, Liu L, Kang CH, Wang WC, Xu J, Guan P, Tan W, Yu CJ, Yang G, Loon Sihoe AD, Chen Y, Choi YY, Kim JS, Yoon HI, Park IK, Xu P, He Q, Wang CL, Hung HH, Vermeulen RCH, Cheng I, Wu J, Lim WY, Tsai FY, Chan JKC, Li J, Chen H, Lin HC, Jin L, Liu J, Sawada N, Yamaji T, Wyatt K, Li SA, Ma H, Zhu M, Wang Z, Cheng S, Li X, Ren Y, Chao A, Iwasaki M, et al. (複数名のため一部抜粋して記載。詳細は掲載先をご参照ください). Stratifying Lung Adenocarcinoma Risk with Multi-ancestry Polygenic Risk Scores in East Asian Never-Smokers. medRxiv : the preprint server for health sciences, 2024.06.26.24309127, 2024
27. Kaseda K, Asakura K, Shintani Y, Okami J, Toyooka S, Sato Y, Watanabe SI, Chida M, Suzuki H, Miyaoka E, Yoshino I, Date H. Surgically resected sarcomatoid carcinoma of the lung: a nationwide retrospective study in 2010. BMC cancer, 24:938, 2024
28. Nakagawa K, Yotsukura M, Mimae T, Hattori A, Miyoshi T, Isaka M, Endo M, Tsutani Y, Isaka T, Maniwa T, Nakajima R, Yoshioka H, Takei H, Aokage K, Watanabe SI. The Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group: outstanding contribution and entering a new phase. Japanese journal of clinical oncology, 54:1237-1243, 2024
29. Watanabe SI, Yotsukura M, Miyoshi T, Hattori A, Isaka T, Maniwa T, Isaka M, Yoshioka H, Endo M, Mimae T, Tsutani Y, Nakagawa K, Aokage K. Updated review of perioperative treatment for non-small-cell lung cancer in the new era of immune checkpoint inhibitors: past, present, and future. Japanese journal of clinical oncology, 54:1244-1253, 2024
30. Fujiwara Y, Takahashi RU, Saito M, Umakoshi M, Shimada Y, Koyama K, Yatabe Y, Watanabe SI, Koyota S, Minamiya Y, Tahara H, Kono K, Shiraishi K, Kohno T, Goto A, Tsuchiya N. Oncofetal IGF2BP3-mediated control of microRNA structural diversity in the malignancy of early-stage lung adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 121:e2407016121, 2024
31. Asada K, Kaneko S, Takasawa K, Shiraishi K, Shinkai N, Shimada Y, Takahashi S, Machino H, Kobayashi K, Bolatkan A, Komatsu M, Yamada M, Miyake M, Watanabe H, Tateishi A, Mizuno T, Okubo Y, Mukai M, Yoshida T, Yoshida Y, Horinouchi H, Watanabe SI, Ohe Y, Yatabe Y, Kohno T, Hamamoto R. Multi-omics and clustering analyses reveal the mechanisms underlying unmet needs for patients with lung adenocarcinoma and identify potential therapeutic targets. Molecular cancer, 23:182, 2024
32. Miyoshi T, Aokage K, Watanabe SI, Ito H, Sakakura N, Mun M, Yamashita M, Ohde Y, Aoki T, Nishio W, Taguri M, Tsuboi M. The effect of epidermal growth factor receptor mutation on adjuvant chemotherapy with tegafur/uracil for patients with completely resected, non-lymph node metastatic non-small cell lung cancer (> 2 cm): a multicenter, retrospective, observational study as exploratory analysis of the CSPOR-LC03 study. Japanese journal of clinical oncology, 54:1185-1193, 2024
33. Ohashi K, Nishito Y, Fukuda H, Sadahiro R, Yoshida Y, Watanabe SI, Motoi N, Sonobe Y, Mizuno H, Tsunoda H, Tatsumi K, Suzuki T, Ochiai A, Aoki K. Author Correction: Neutrophil-to-lymphocyte ratio is a prognostic factor reflecting immune condition of tumor microenvironment in squamous cell lung cancer. Scientific reports, 14:30457, 2024
34. Yamamoto G, Tanaka K, Kamata R, Saito H, Yamamori-Morita T, Nakao T, Liu J, Mori S, Yagishita S, Hamada A, Shinno Y, Yoshida T, Horinouchi H, Ohe Y, Watanabe SI, Yatabe Y, Kitai H, Konno S, Kobayashi SS, Ohashi A. WEE1 confers resistance to KRAS(G12C) inhibitors in non-small cell lung cancer. Cancer letters, 611:217414, 2024
35. Yotsukura M, Yoshida Y, Nakagawa K, Watanabe SI. Prognostic Indicator for Pleural Mesothelioma. Annals of thoracic surgery short reports, 2:597-602, 2024